Malvern, Pennsylvania-based Neuronetics develops products aimed at improving the life of patients with neuro health disorders. Its latest updates to NeuroStar particularly improve connectivity for providers with restricted networks.
NeuroStar, a non-drug, non-invasive treatment can improve the quality of life for neuro health patients when traditional medication fails. The transcranial magnetic stimulation (TMS) treatment holds FDA clearance for adults with major depressive disorder (MDD). It also has authorization as an adjunct for adults with obsessive-compulsive disorder (OCD). The company said the FDA also cleared it for adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression).
Users of the NeuroStar 3.7 platform can now access features and benefits previously exclusive to TrakStar cloud customers. All the while, they maintain HIPAA compliance and patient security. Neuronetics said the feature allows for data collection from additional practices. This enhances the ability to gather insights from a broader cross-section of practices.
“By integrating Wi-Fi capability into the NeuroStar system, providers now have greater flexibility in where they place their NeuroStar system and have access to more connectivity options for TrakStar,” said Cory Anderson, Neuronetics SVP of R&D and clinical. “This latest advancement demonstrates our continued commitment to invest in technology that streamlines practice operation and allows improved access to TrakStar insights.”
